More than hot flashes: Women raise awareness about menopause symptoms and work
The Mayo Clinic estimates that menopause symptoms lead to $1.8 billion in lost work time per year in the U.S. About 5% of ...
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and ...
GlobalData on MSN5d
Genentech wins FDA approval for second stroke treatment
Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Fierce Biotech2d
Roche to house its CVRM research work at Harvard's new research campus
Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it ...
Roche to open innovation center at new Harvard campus in Allston that could employ hundreds
Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise ...
GEN - Genetic Engineering and Biotechnology News1d
Roche Genentech Innovation Center Boston Launched at Harvard’s Enterprise Research Campus
The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.
EMS12d
FDA approves clot-dissolving agent for treatment of acute ischemic stroke
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
PMLive4d
Roche’s Genentech granted FDA approval for TNKase in acute ischaemic stroke
Roche’s Genentech unit has received approval from the US Food and Drug Administration (FDA) for TNKase (tenecteplase) in ...
Contract Pharma5d
Genentech’s TNKase Approved by FDA for Treatment of Strokes
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
Genentech receives FDA acceptance for Gazyva sBLA
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...
Fierce Pharma5d
Roche gains label expansion for heart attack medicine TNKase to treat acute ischemic stroke
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
Morningstar6d
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot ...